ID   PDE8B_HUMAN             Reviewed;         885 AA.
AC   O95263; Q5J7V7; Q86XK8; Q8IUJ7; Q8IUJ8; Q8IUJ9; Q8IUK0; Q8N3T2;
DT   30-MAY-2000, integrated into UniProtKB/Swiss-Prot.
DT   22-AUG-2003, sequence version 2.
DT   15-MAR-2017, entry version 169.
DE   RecName: Full=High affinity cAMP-specific and IBMX-insensitive 3',5'-cyclic phosphodiesterase 8B;
DE            Short=HsPDE8B;
DE            EC=3.1.4.53 {ECO:0000269|PubMed:12681444};
DE   AltName: Full=Cell proliferation-inducing gene 22 protein;
GN   Name=PDE8B; ORFNames=PIG22;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA] (ISOFORMS 1; 2 AND 6), AND
RP   TISSUE SPECIFICITY.
RX   PubMed=12372422; DOI=10.1016/S0006-291X(02)02371-9;
RA   Hayashi M., Shimada Y., Nishimura Y., Hama T., Tanaka T.;
RT   "Genomic organization, chromosomal localization, and alternative
RT   splicing of the human phosphodiesterase 8B gene.";
RL   Biochem. Biophys. Res. Commun. 297:1253-1258(2002).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1; 2; 3 AND 4), CATALYTIC
RP   ACTIVITY, ENZYME REGULATION, AND TISSUE SPECIFICITY.
RC   TISSUE=Thyroid;
RX   PubMed=12681444; DOI=10.1016/S0898-6568(02)00146-8;
RA   Gamanuma M., Yuasa K., Sasaki T., Sakurai N., Kotera J., Omori K.;
RT   "Comparison of enzymatic characterization and gene organization of
RT   cyclic nucleotide phosphodiesterase 8 family in humans.";
RL   Cell. Signal. 15:565-574(2003).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 5).
RA   Kim J.W.;
RT   "Identification of a human proliferation-inducing gene.";
RL   Submitted (SEP-2003) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 5).
RC   TISSUE=Testis;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 227-885 (ISOFORM 1).
RX   PubMed=9784418; DOI=10.1006/bbrc.1998.9379;
RA   Hayashi M., Matsushima K., Ohashi H., Tsunoda H., Murase S.,
RA   Kawarada Y., Tanaka T.;
RT   "Molecular cloning and characterization of human PDE8B, a novel
RT   thyroid-specific isozyme of 3',5'-cyclic nucleotide
RT   phosphodiesterase.";
RL   Biochem. Biophys. Res. Commun. 250:751-756(1998).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 43-885 (ISOFORM 1).
RC   TISSUE=Amygdala;
RX   PubMed=17974005; DOI=10.1186/1471-2164-8-399;
RA   Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U.,
RA   Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H.,
RA   Heubner D., Hoerlein A., Michel G., Wedler H., Koehrer K.,
RA   Ottenwaelder B., Poustka A., Wiemann S., Schupp I.;
RT   "The full-ORF clone resource of the German cDNA consortium.";
RL   BMC Genomics 8:399-399(2007).
RN   [8]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-517, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [9]
RP   INVOLVEMENT IN ADSD1.
RX   PubMed=20085714; DOI=10.1016/j.ajhg.2009.12.003;
RA   Appenzeller S., Schirmacher A., Halfter H., Baumer S., Pendziwiat M.,
RA   Timmerman V., De Jonghe P., Fekete K., Stogbauer F., Ludemann P.,
RA   Hund M., Quabius E.S., Ringelstein E.B., Kuhlenbaumer G.;
RT   "Autosomal-dominant striatal degeneration is caused by a mutation in
RT   the phosphodiesterase 8B gene.";
RL   Am. J. Hum. Genet. 86:83-87(2010).
RN   [10]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-517, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S.,
RA   Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full
RT   phosphorylation site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [11]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-517, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [12]
RP   VARIANT PPNAD3 PRO-305, AND CHARACTERIZATION OF VARIANT PPNAD3
RP   PRO-305.
RX   PubMed=18431404; DOI=10.1038/ejhg.2008.85;
RA   Horvath A., Giatzakis C., Tsang K., Greene E., Osorio P., Boikos S.,
RA   Libe R., Patronas Y., Robinson-White A., Remmers E., Bertherat J.,
RA   Nesterova M., Stratakis C.A.;
RT   "A cAMP-specific phosphodiesterase (PDE8B) that is mutated in adrenal
RT   hyperplasia is expressed widely in human and mouse tissues: a novel
RT   PDE8B isoform in human adrenal cortex.";
RL   Eur. J. Hum. Genet. 16:1245-1253(2008).
CC   -!- FUNCTION: Hydrolyzes the second messenger cAMP, which is a key
CC       regulator of many important physiological processes. May be
CC       involved in specific signaling in the thyroid gland.
CC   -!- CATALYTIC ACTIVITY: Adenosine 3',5'-cyclic phosphate + H(2)O =
CC       adenosine 5'-phosphate. {ECO:0000269|PubMed:12681444}.
CC   -!- COFACTOR:
CC       Name=a divalent metal cation; Xref=ChEBI:CHEBI:60240;
CC         Evidence={ECO:0000250};
CC       Note=Binds 2 divalent metal cations per subunit. Site 1 may
CC       preferentially bind zinc ions, while site 2 has a preference for
CC       magnesium and/or manganese ions. {ECO:0000250};
CC   -!- ENZYME REGULATION: Inhibited by dipyridimole. Insensitive to
CC       selective PDE inhibitors including rolipram and milrinone as well
CC       as to the non-selective inhibitor, IBMX. Unaffected by cGMP.
CC       {ECO:0000269|PubMed:12681444}.
CC   -!- PATHWAY: Purine metabolism; 3',5'-cyclic AMP degradation; AMP from
CC       3',5'-cyclic AMP: step 1/1.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=6;
CC       Name=1; Synonyms=PDE8B1;
CC         IsoId=O95263-1; Sequence=Displayed;
CC         Note=Major isoform.;
CC       Name=2; Synonyms=PDE8B2, PDE8B3;
CC         IsoId=O95263-2; Sequence=VSP_008084;
CC       Name=3; Synonyms=PDE8B3;
CC         IsoId=O95263-3; Sequence=VSP_008085;
CC       Name=4; Synonyms=PDE8B4;
CC         IsoId=O95263-4; Sequence=VSP_008082;
CC       Name=5;
CC         IsoId=O95263-5; Sequence=VSP_008081;
CC         Note=No experimental confirmation available.;
CC       Name=6; Synonyms=PDE8B2;
CC         IsoId=O95263-6; Sequence=VSP_008083;
CC   -!- TISSUE SPECIFICITY: Abundantly expressed in the thyroid. Also very
CC       weakly expressed in brain, spinal cord and placenta. In the
CC       thyroid isoform 1 predominates, and isoforms 2 and 6 are also
CC       highly expressed. In the placenta isoforms 1 and 2 are expressed
CC       equally. In the brain isoform 2 predominates.
CC       {ECO:0000269|PubMed:12372422, ECO:0000269|PubMed:12681444}.
CC   -!- DOMAIN: Composed of a C-terminal catalytic domain containing two
CC       putative divalent metal sites and an N-terminal regulatory domain.
CC   -!- DISEASE: Striatal degeneration, autosomal dominant 1 (ADSD1)
CC       [MIM:609161]: A movement disorder affecting the striatal part of
CC       the basal ganglia and characterized by bradykinesia, dysarthria
CC       and muscle rigidity. These symptoms resemble idiopathic Parkinson
CC       disease, but tremor is not present. {ECO:0000269|PubMed:20085714}.
CC       Note=The disease is caused by mutations affecting the gene
CC       represented in this entry.
CC   -!- DISEASE: Primary pigmented nodular adrenocortical disease 3
CC       (PPNAD3) [MIM:614190]: A rare bilateral adrenal defect causing
CC       ACTH-independent Cushing syndrome. Macroscopic appearance of the
CC       adrenals is characteristic with small pigmented micronodules
CC       observed in the cortex. Adrenal glands show overall normal size
CC       and weight, and multiple small yellow-to-dark brown nodules
CC       surrounded by a cortex with a uniform appearance. Microscopically,
CC       there are moderate diffuse cortical hyperplasia with mostly
CC       nonpigmented nodules, multiple capsular deficits and massive
CC       circumscribed and infiltrating extra-adrenal cortical excrescences
CC       with micronodules. Clinical manifestations of Cushing syndrome
CC       include facial and truncal obesity, abdominal striae, muscular
CC       weakness, osteoporosis, arterial hypertension, diabetes.
CC       {ECO:0000269|PubMed:18431404}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the cyclic nucleotide phosphodiesterase
CC       family. PDE8 subfamily. {ECO:0000305}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AY129948; AAN71723.1; -; mRNA.
DR   EMBL; AY129949; AAN71724.1; -; mRNA.
DR   EMBL; AY129950; AAN71725.1; -; Genomic_DNA.
DR   EMBL; AY129950; AAN71726.1; -; Genomic_DNA.
DR   EMBL; AY129950; AAN71727.1; -; Genomic_DNA.
DR   EMBL; AB085824; BAC53762.1; -; mRNA.
DR   EMBL; AB085825; BAC53763.1; -; mRNA.
DR   EMBL; AB085826; BAC53764.1; -; mRNA.
DR   EMBL; AB085827; BAC53765.1; -; mRNA.
DR   EMBL; AY423729; AAS00492.1; -; mRNA.
DR   EMBL; CH471084; EAW95803.1; -; Genomic_DNA.
DR   EMBL; BC043209; -; NOT_ANNOTATED_CDS; mRNA.
DR   EMBL; AF079529; AAC69564.2; -; mRNA.
DR   EMBL; AL831924; CAD38584.1; -; mRNA.
DR   CCDS; CCDS34190.1; -. [O95263-3]
DR   CCDS; CCDS34191.1; -. [O95263-6]
DR   CCDS; CCDS34192.1; -. [O95263-2]
DR   CCDS; CCDS34193.1; -. [O95263-4]
DR   CCDS; CCDS4037.1; -. [O95263-1]
DR   PIR; JE0293; JE0293.
DR   RefSeq; NP_001025022.1; NM_001029851.2. [O95263-2]
DR   RefSeq; NP_001025023.1; NM_001029852.2. [O95263-3]
DR   RefSeq; NP_001025024.1; NM_001029853.2. [O95263-4]
DR   RefSeq; NP_001025025.1; NM_001029854.2. [O95263-6]
DR   RefSeq; NP_003710.1; NM_003719.3. [O95263-1]
DR   UniGene; Hs.584830; -.
DR   ProteinModelPortal; O95263; -.
DR   SMR; O95263; -.
DR   BioGrid; 114177; 1.
DR   IntAct; O95263; 1.
DR   STRING; 9606.ENSP00000264917; -.
DR   BindingDB; O95263; -.
DR   ChEMBL; CHEMBL4408; -.
DR   DrugBank; DB00201; Caffeine.
DR   DrugBank; DB00920; Ketotifen.
DR   GuidetoPHARMACOLOGY; 1308; -.
DR   iPTMnet; O95263; -.
DR   PhosphoSitePlus; O95263; -.
DR   BioMuta; PDE8B; -.
DR   UCD-2DPAGE; O95263; -.
DR   MaxQB; O95263; -.
DR   PaxDb; O95263; -.
DR   PeptideAtlas; O95263; -.
DR   PRIDE; O95263; -.
DR   DNASU; 8622; -.
DR   Ensembl; ENST00000264917; ENSP00000264917; ENSG00000113231. [O95263-1]
DR   Ensembl; ENST00000333194; ENSP00000331336; ENSG00000113231. [O95263-3]
DR   Ensembl; ENST00000340978; ENSP00000345446; ENSG00000113231. [O95263-6]
DR   Ensembl; ENST00000342343; ENSP00000345646; ENSG00000113231. [O95263-4]
DR   Ensembl; ENST00000346042; ENSP00000330428; ENSG00000113231. [O95263-2]
DR   Ensembl; ENST00000505283; ENSP00000423461; ENSG00000113231. [O95263-5]
DR   GeneID; 8622; -.
DR   KEGG; hsa:8622; -.
DR   UCSC; uc003kfa.4; human. [O95263-1]
DR   CTD; 8622; -.
DR   DisGeNET; 8622; -.
DR   GeneCards; PDE8B; -.
DR   H-InvDB; HIX0004971; -.
DR   HGNC; HGNC:8794; PDE8B.
DR   HPA; HPA036911; -.
DR   HPA; HPA036912; -.
DR   MalaCards; PDE8B; -.
DR   MIM; 603390; gene.
DR   MIM; 609161; phenotype.
DR   MIM; 614190; phenotype.
DR   neXtProt; NX_O95263; -.
DR   OpenTargets; ENSG00000113231; -.
DR   Orphanet; 228169; Autosomal dominant striatal neurodegeneration.
DR   Orphanet; 189439; Primary pigmented nodular adrenocortical disease.
DR   PharmGKB; PA33142; -.
DR   eggNOG; KOG1229; Eukaryota.
DR   eggNOG; ENOG410XP9B; LUCA.
DR   GeneTree; ENSGT00760000118889; -.
DR   HOVERGEN; HBG053544; -.
DR   KO; K18437; -.
DR   OMA; DHRQTQN; -.
DR   OrthoDB; EOG091G0337; -.
DR   PhylomeDB; O95263; -.
DR   TreeFam; TF314638; -.
DR   BRENDA; 3.1.4.53; 2681.
DR   Reactome; R-HSA-418555; G alpha (s) signalling events.
DR   UniPathway; UPA00762; UER00747.
DR   ChiTaRS; PDE8B; human.
DR   GeneWiki; PDE8B; -.
DR   GenomeRNAi; 8622; -.
DR   PRO; PR:O95263; -.
DR   Proteomes; UP000005640; Chromosome 5.
DR   Bgee; ENSG00000113231; -.
DR   CleanEx; HS_PDE8B; -.
DR   ExpressionAtlas; O95263; baseline and differential.
DR   Genevisible; O95263; HS.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0004115; F:3',5'-cyclic-AMP phosphodiesterase activity; TAS:Reactome.
DR   GO; GO:0004114; F:3',5'-cyclic-nucleotide phosphodiesterase activity; NAS:UniProtKB.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0006198; P:cAMP catabolic process; IEA:UniProtKB-UniPathway.
DR   GO; GO:0009187; P:cyclic nucleotide metabolic process; NAS:UniProtKB.
DR   GO; GO:0046676; P:negative regulation of insulin secretion; IEA:Ensembl.
DR   GO; GO:0007165; P:signal transduction; IEA:InterPro.
DR   CDD; cd00130; PAS; 1.
DR   Gene3D; 1.10.1300.10; -; 1.
DR   InterPro; IPR003607; HD/PDEase_dom.
DR   InterPro; IPR000014; PAS.
DR   InterPro; IPR023088; PDEase.
DR   InterPro; IPR002073; PDEase_catalytic_dom.
DR   InterPro; IPR023174; PDEase_CS.
DR   InterPro; IPR013938; PDEase_PDE8.
DR   Pfam; PF13426; PAS_9; 1.
DR   Pfam; PF08629; PDE8; 1.
DR   Pfam; PF00233; PDEase_I; 1.
DR   PRINTS; PR00387; PDIESTERASE1.
DR   SMART; SM00471; HDc; 1.
DR   SMART; SM00091; PAS; 1.
DR   SUPFAM; SSF55785; SSF55785; 1.
DR   TIGRFAMs; TIGR00229; sensory_box; 1.
DR   PROSITE; PS50112; PAS; 1.
DR   PROSITE; PS00126; PDEASE_I; 1.
PE   1: Evidence at protein level;
KW   Alternative splicing; cAMP; Complete proteome; Cushing syndrome;
KW   Disease mutation; Hydrolase; Metal-binding; Phosphoprotein;
KW   Reference proteome.
FT   CHAIN         1    885       High affinity cAMP-specific and IBMX-
FT                                insensitive 3',5'-cyclic
FT                                phosphodiesterase 8B.
FT                                /FTId=PRO_0000198840.
FT   DOMAIN      267    338       PAS. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00140}.
FT   REGION      590    868       Catalytic. {ECO:0000250}.
FT   ACT_SITE    615    615       Proton donor.
FT                                {ECO:0000250|UniProtKB:O76083}.
FT   METAL       619    619       Divalent metal cation 1; via tele
FT                                nitrogen. {ECO:0000250|UniProtKB:O60658}.
FT   METAL       655    655       Divalent metal cation 1; via tele
FT                                nitrogen. {ECO:0000250|UniProtKB:O60658}.
FT   METAL       656    656       Divalent metal cation 1.
FT                                {ECO:0000250|UniProtKB:O60658}.
FT   METAL       656    656       Divalent metal cation 2.
FT                                {ECO:0000250|UniProtKB:O60658}.
FT   METAL       781    781       Divalent metal cation 1.
FT                                {ECO:0000250|UniProtKB:O60658}.
FT   MOD_RES     517    517       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:20068231,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES     754    754       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:E9Q4S1}.
FT   VAR_SEQ       1    535       Missing (in isoform 5).
FT                                {ECO:0000303|PubMed:15489334,
FT                                ECO:0000303|Ref.3}.
FT                                /FTId=VSP_008081.
FT   VAR_SEQ     114    133       Missing (in isoform 4).
FT                                {ECO:0000303|PubMed:12681444}.
FT                                /FTId=VSP_008082.
FT   VAR_SEQ     293    389       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:12372422,
FT                                ECO:0000303|PubMed:12681444}.
FT                                /FTId=VSP_008084.
FT   VAR_SEQ     293    339       Missing (in isoform 6).
FT                                {ECO:0000303|PubMed:12372422}.
FT                                /FTId=VSP_008083.
FT   VAR_SEQ     456    510       Missing (in isoform 3).
FT                                {ECO:0000303|PubMed:12681444}.
FT                                /FTId=VSP_008085.
FT   VARIANT     305    305       H -> P (in PPNAD3; shows significantly
FT                                higher cyclic AMP levels after
FT                                transfection with the mutant protein than
FT                                after transfection with the wild-type,
FT                                indicating an impaired ability of the
FT                                mutant protein to degrade cAMP;
FT                                dbSNP:rs121918360).
FT                                {ECO:0000269|PubMed:18431404}.
FT                                /FTId=VAR_066503.
FT   CONFLICT    147    147       G -> R (in Ref. 7; CAD38584).
FT                                {ECO:0000305}.
SQ   SEQUENCE   885 AA;  98979 MW;  DB4F763E51F745A3 CRC64;
     MGCAPSIHVS QSGVIYCRDS DESSSPRQTT SVSQGPAAPL PGLFVQTDAA DAIPPSRASG
     PPSVARVRRA RTELGSGSSA GSAAPAATTS RGRRRHCCSS AEAETQTCYT SVKQVSSAEV
     RIGPMRLTQD PIQVLLIFAK EDSQSDGFWW ACDRAGYRCN IARTPESALE CFLDKHHEII
     VIDHRQTQNF DAEAVCRSIR ATNPSEHTVI LAVVSRVSDD HEEASVLPLL HAGFNRRFME
     NSSIIACYNE LIQIEHGEVR SQFKLRACNS VFTALDHCHE AIEITSDDHV IQYVNPAFER
     MMGYHKGELL GKELADLPKS DKNRADLLDT INTCIKKGKE WQGVYYARRK SGDSIQQHVK
     ITPVIGQGGK IRHFVSLKKL CCTTDNNKQI HKIHRDSGDN SQTEPHSFRY KNRRKESIDV
     KSISSRGSDA PSLQNRRYPS MARIHSMTIE APITKVINII NAAQENSPVT VAEALDRVLE
     ILRTTELYSP QLGTKDEDPH TSDLVGGLMT DGLRRLSGNE YVFTKNVHQS HSHLAMPITI
     NDVPPCISQL LDNEESWDFN IFELEAITHK RPLVYLGLKV FSRFGVCEFL NCSETTLRAW
     FQVIEANYHS SNAYHNSTHA ADVLHATAFF LGKERVKGSL DQLDEVAALI AATVHDVDHP
     GRTNSFLCNA GSELAVLYND TAVLESHHTA LAFQLTVKDT KCNIFKNIDR NHYRTLRQAI
     IDMVLATEMT KHFEHVNKFV NSINKPMAAE IEGSDCECNP AGKNFPENQI LIKRMMIKCA
     DVANPCRPLD LCIEWAGRIS EEYFAQTDEE KRQGLPVVMP VFDRNTCSIP KSQISFIDYF
     ITDMFDAWDA FAHLPALMQH LADNYKHWKT LDDLKCKSLR LPSDS
//
